[DOI] [PubMed] [Google Scholar] 118.Mentis N., Vardarli I., Kthe L.D., Holst J.J., Deacon C.F., Theodorakis M., Meier J.J., Nauck M.A
Hepatic function plays a minimal role in GLP-1 elimination, as these medications are primarily degraded by proteolytic enzymes throughout the body rather than hepatic metabolism
Five stages of evolving -cell dysfunction during progression to diabetes
Real-world prescription data from Germany indicated that, among those switching between GLP-1 receptor agonists (exenatide twice daily, exenatide once weekly, dulaglutide once weekly, or liraglutide once daily), post-switch persistence rates were greater among those receiving dulaglutide once weekly compared with liraglutide once daily and exenatide twice daily (Figure 1) (57)
They typically give mega-doses (10-25 mg) to help those with significant B12 deficiency symptoms